NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

InMode Ltd. (INMD) Stock Analysis

InMode Ltd. (INMD) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

INMD

$14.91

+$0.07 (+0.47%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare INMD with… →

INMD Key Statistics

As of Sep 4, 2026
Trading
Open
$14.79
Previous Close
$14.84
Day's Range
14.77–14.94
52-Week Range
12.72–16.74
Volume
449.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.86
Valuation
Market Cap
$857.98M
P/E Ratio
12.32
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
10.87
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.83
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.29
EPS (ttm)Profit attributable to each share over the last twelve months.
1.21
Financials (FY)
Revenue (FY)
$370.50M−6.16%
Net Income (FY)
$93.83M−48.24%
Profit marginThe share of revenue left as profit after all costs and taxes.
20.69%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
57.54M
1-Year Return
+3.47%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
611.67K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

INMD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+1.50%
2025−12.04%
2024−24.91%
2023−37.70%
2022−49.42%
2021+197.30%
2020+21.12%
2019 (partial year)+188.87%

As of September 4, 2026.

INMD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$370.50M$93.83M25.3%
2024$394.82M$181.28M45.9%
2023$492.05M$197.92M40.2%
2022$454.27M$161.52M35.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$370.50M$290.97M$85.39M$93.83M25.3%
2024$394.82M$317.07M$112.53M$181.28M45.9%
2023$492.05M$411.34M$195.66M$197.92M40.2%
2022$454.27M$380.79M$197.85M$161.52M35.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

INMD Valuation vs Medical Devices Median

Median of 151 stocks
MetricINMDMedical Devices medianvs median
P/E12.3226.8054% below
P/S ratio2.292.9823% below
Profit margin20.69%−1.69%22.4 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

InMode Ltd. (INMD) carries a market capitalisation of $857.98M. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 660.

Over the past 52 weeks the price has ranged from $12.72 to $16.74. INMD last closed at $14.91 on September 4, 2026. That is +$0.07 (+0.47%) against the previous close. The latest close sits 17.22% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $370.50M. Against the prior fiscal year total of $394.82M, that is a change of −6.16%. The same year closed with net income of $93.83M. That is −48.24% against the prior fiscal year. Profit margin runs at 20.69%. That is 22.4 percentage points above the Medical Devices median of −1.69%. Trailing earnings per share are 1.21.

Across the 4 fiscal years on file, revenue moves from $454.27M in 2022 to $370.50M in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

INMD trades at a trailing price-to-earnings ratio of 12.32. That is 54.03% below the Medical Devices median of 26.8. The forward P/E on file is 10.87. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.83. Measured against sales, the shares trade at 2.29 times revenue. On price-to-sales that is 23.04% below the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

Over the trailing twelve months the price has returned +3.47%. Across 5 years the annualized return works out at −25.93%. The reported beta is 1.86. Annualized volatility over the trailing 7 years is 59.08%.

Growth & Income

The record shows no dividend for INMD.

So far in 2026 the price is +1.50%. Across the complete calendar years on file, 2021 returned +197.30% and 2022 returned −49.42%. Of the 6 complete calendar years on file, 2 finished higher.

Peer Comparison

InMode Ltd. (INMD) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
InMode Ltd. INMD $857.98M 12.3
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. InMode Ltd. trades at a P/E of 12.3.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About InMode Ltd.

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.

Visit website →